What is Anamorelin and what is its therapeutic effect?

Anamorelin (Anamorelin) is a new oral small molecule drug that mainly acts on the gastrin/growth hormone secretion pathway and is classified as a selective ghrelin receptor agonist. Its most prominent application areas are nutritional support and weight management in patients with cancer cachexia. Cancer cachexia is a metabolic syndrome that is closely related to tumor progression and is common in patients with advanced cancer. It is characterized by severe weight loss, muscle loss, and loss of appetite, which often has a serious impact on patients' quality of life and treatment tolerance. By imitating the action of the gastric hunger hormone ghrelin, Anamorelin promotes the release of growth hormone from the hypothalamus, thereby enhancing appetite, increasing food intake, further stimulating protein synthesis, promoting muscle formation, and comprehensively improving physical fitness.

Unlike traditional nutritional support or steroid orexigenic drugs, the advantage of anamorelin is that it can simultaneously improve body weight and muscle mass, which is particularly important in combating the systemic debilitating state caused by cancer. By acting on the central appetite regulation center and peripheral metabolic pathways, it not only increases the patient's desire to eat, but also indirectly regulates the levels of inflammatory factors and metabolic status, and has a positive impact on the overall physical status. Although anamorelin is not a direct anti-cancer drug, it provides an important supportive treatment option in comprehensive cancer treatment, helping to improve patients' tolerance to chemotherapy, radiotherapy and other treatments, and may prolong survival time.

The drug is currently approved for the treatment of cachexia caused by non-small cell lung cancer in Japan and other countries, and is also undergoing clinical research and review in Europe and the United States. Due to its relatively unique mechanism and relatively mild side effect spectrum, it has become an important research focus in the field of cancer supportive care in recent years. If it can be approved on a wider scale, it is expected to become a key means to improve the quality of life for patients with various tumors including lung cancer, gastric cancer, pancreatic cancer, etc.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/